Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer

Inclusion criteria

• diagnosed with stage I-IV ovarian, peritoneal or fallopian tube cancer
• completed first-line taxane and platinum-based chemotherapy 1-4 months prior to being enrolled in the study (can be on bevacizumab maintenance)
• in remission of their disease at the time of enrollment between 21 and 70 years of age
• fluent in English
• in the judgment of the consenting professional, have capacity to give consent

Healthy Control Inclusion Criteria:

• no diagnosis of cancer except basal cell carcinoma
• between 21 and 70 years of age
• fluent in English
• has a mini-mental state exam (MMSE) score of 26 or higher
• in the judgment of the consenting professional, have capacity to give consent

Exclusion criteria

• active or recurrent disease, or diagnosis of another cancer (except basal cell carcinoma) as per medical records at the time of enrollment
• exposure to chemotherapy or radiation therapy for any medical condition unrelated to ovarian cancer
• on hormonal therapy at the time of enrollment
• neurological disorder or moderate to severe head trauma (loss of consciousness > 60 min)
• neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.
• self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia
• unable to complete cognitive tests
• with standard contraindications to MRI examinations

Healthy Control Exclusion Criteria:

• exposure to chemotherapy or radiation therapy for any medical condition
• on hormone replacement therapy at the time of enrollment
• neurological disorder or moderate to severe head trauma (loss of consciousness > 60 min)
• neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.